The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck’s patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.
A judge has found Pfizer’s patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy’s Laboraties of threatening to infringe its patent for Revlimid with the planned launch of a generic version of the blockbuster cancer drug in Australia.
An Australian fashion designer suing Katy Perry over the rights to use the Katy Perry trade mark in Australia is a “calculating and dishonest witness” whose “utterly dishonest” testimony should not be believed, counsel for the pop star said during closing submissions.
A judge has revoked two patents held by national fitness chain F45 for a computer-run trainer workout system.
Plumbing company Repipe has asked the High Court to take up its case centred on the controversial issue of patent eligibility for computer-implemented inventions, seeking to overturn a judgment it argues sets a new and impermissible test.
Apple has fired back in a lawsuit alleging its iPhone and iPad devices equipped with Touch ID and Face ID technology infringe patents held by an Australian non-practicing entity, hitting the company with its own case claiming the patents are invalid.
Burger giant Hungry Jack’s has lost its bid to have McDonald’s hand over test results showing the “pre-cooked” weight of its Big Mac beef patties, with a judge finding they were not relevant to whether the rival’s Big Jack burger had 25 per cent “more Aussie beef”.
The Full Federal Court has shot down plumbing company Repipe’s appeal of a decision rejecting its innovation patents for a claimed computer-implemented invention, saying it only addressed issues in business operations rather than improving on computer technology.
Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.